Clinical Trial Update: Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating brentuximab vedotin before autologous stem cell transplant in Hodgkin lymphoma; the study has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-04-26